Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Invasive Breast Cancer, Stage III Breast...
Phase PHASE3
Enrollment 858
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

This clinical research aims to determine if concurrent chemotherapy and radiation therapy is more effective than sequential chemotherapy and radiation therapy for patients with stage IIB-III breast cancer. It seeks to answer the following key questions: 1. When compared to sequential treatment, does concurrent chemoradiotherapy increase disease-free survival? 2. What effects does concurrent treatment have on post-operative look, quality of life, and side effects including arm swelling (lymphoedema)? 3. What are each treatment approach's financial costs? Researchers will compare the following to groups: Arm A: Participants in the sequential treatment group will first undergo chemotherapy and then radiation. and Arm B: Participants in the concurrent treatment group will undergo radiation therapy while undergoing chemotherapy. Participants are going to: 1. Get the usual chemotherapy (taxanes and/or anthracyclines). 2. Receive radiation therapy for three to four weeks. 3. Have follow-up visits every 6months for 5years to check for cancer recurrence, side effects, and quality of life.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Chemoradiation — This intervention will consist of getting chemotherapy followed by radiotherapy, i.e, in a sequential manner
  • Drug: Chemoradiation — This intervention will consist of getting chemotherapy and radiotherapy at the same time, i.e, in a concurrent manner.

Primary Outcomes

  • Study the 3-year Disease Free Survival. (From enrollment to 3 years after treatment at six months intervals.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-05-14
Completion: 2031-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 858 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Dr. Tabassum Wadasadawala
Contact Information
Study Contact:
Tabassum Wadasadawala, MD, DNB Radiotherapy
(+91-22) 24177026
drtabs.radonc@gmail.com
Rohit Vadgaonkar
+910167 224 1241
dr.ravad@gmail.com
Homi Bhabha Cancer Hospital & Research Centre
Rohit Vadgaonkar
Homi Bhabha Cancer Hospital & Research Centre
Interventions
  • Drug: Chemoradiation — This intervention will consist of getting chemotherapy followed by radiotherapy, i.e, in a sequential manner
  • Drug: Chemoradiation — This intervention will consist of getting chemotherapy and radiotherapy at the same time, i.e, in a concurrent manner.
Study Locations (5 sites)
Homi Bhabha Cancer Hospital & Research Centre, Vishkhapatnam, Andhra Pradesh 530053 India
Tata Memorial Centre, Mumbai, Maharasthra 400012 India
Homi Bhabha Cancer Hospital and Research Centre, New Chandigarh, Punjab 140901 India
Homi Bhabha Cancer Hospital, Sangrur, Sangrur, Punjab 148001 India
Mahamana Pandit Madan Mohan Malviya Cancer Centre, Varanasi, Uttar Pradesh 221005 India
Eligibility Criteria
Inclusion Criteria: 1. Pathologically confirmed invasive breast cancer 2. Stage IIB-III invasive breast cancer (AJCC 8th edition) 3. Patients planned for adjuvant chemotherapy and adjuvant radiotherapy 4. Patients fit to receive adjuvant chemotherapy and radiotherapy 5. Age \> 18 years Exclusion Criteria: 1. Hypersensitivity to taxanes 2. Patients receiving entire chemotherapy prior to surgery (neoadjuvant setting) 3. Unable or unwilling for regular follow up 4. Bilateral tumour needed RT to both sides 5. Patients planned for RT to oligometastatic sites 6. Unfavourable anatomical factors potentially leading to higher radiotherapy dose to heart and/or lungs (Exceeding the protocol specific mandatory dose constraints). 7. Pregnant patient
Conditions Breast Cancer
Phase PHASE3
Enrollment 1900
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective, randomized, open-label, multicenter phase III study to explore chemotherapy omission in ER+/HER2-endocrine-sensitive breast cancer with 1-3 positive lymph nodes receiving extended (3 year) adjuvant abemaciclib

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: 3-year abemaciclib without chemo — aromatase inhibitors (± ovarian suppression) plus 3-year abemaciclib (100mg bid) without chemotherapy.
  • Drug: treatment of physician's choice — treatment of physician's choice including whether to receive chemotherapy, chemotherapy regimen and endocrine therapy regimen.

Primary Outcomes

  • Invasive disease free survival (5 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-04-02
Completion: 2029-01-01
Eligibility
Age: 18 Years – 80 Years
Sex: FEMALE
Volunteers: false
Enrollment: 1900 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Principal Investigators:
  • Zhimin Shao, MD, PhD (PRINCIPAL_INVESTIGATOR) - Fudan University
Contact Information
Study Contact:
Zhimin Shao, MD, PhD
+86-021-64175590
zhimingshao@yahoo.com
Yin Liu, MD
+8664175590
liuyinfudan@163.com
Zhimin Shao, MD, PhD
+8664175590
zhimingshao@yahoo.com
Zhimin Cancer Shao
Interventions
  • Drug: 3-year abemaciclib without chemo — aromatase inhibitors (± ovarian suppression) plus 3-year abemaciclib (100mg bid) without chemotherapy.
  • Drug: treatment of physician's choice — treatment of physician's choice including whether to receive chemotherapy, chemotherapy regimen and endocrine therapy regimen.
Study Locations (1 sites)
Zhimin Cancer Shao, Shanghai, 200032 China
Eligibility Criteria
Inclusion Criteria: * women aged 18-80 years old; * Patient has localized invasive breast carcinoma with1-3 positive lymph nodes, T1-T2,and is ER+/HER2- confirmed by histopathology after early breast cancer surgery#HER2-negative breast cancer (based on most recently analyzed biopsy) defined as a negative in situ hybridization test or an Immunohistochemistry (IHC) status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (Fluorescence in situ hybridization (FISH), Chromogenic in situ hybridization (CISH) . * ER≥50% * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; * Has adequate organ function meeting the following criteria: (1) adequate bone marrow function: hemoglobin ≥ 90 g/L (no blood transfusion within 14 days); absolute neutrophil count ≥ 1.5 x 109 /L; platelet count ≥ 100 \* 109 /L; (2)adequate liver and kidney function: Alanine Aminotransferase (ALT) ≤ 3×upper limit of normal (ULN), Aspartate Aminotransferase (AST) ≤ 3×ULN, Total Bilirubin (TBIL)≤ 1.5×ULN, serum creatinine ≤ 1×ULN#and with endogenous creatinine clearance rate of \>50 ml/min (Cockcroft-Gault formula). * Participants voluntarily joined the study, has signed informed consent before any trial related activities are conducted, has good compliance and has agreed to follow-up. Exclusion Criteria: * Has received neoadjuvant therapy (include chemotherapy, targeted therapy, radiotherapy or endocrine therapy#; * Has bilateral breast cancer; * Has previous history of additional malignancy, with the exception of adequately treated basal cell carcinoma and cervical carcinoma in situ. * Has metastatic (Stage 4) breast cancer; * Has any ≥T3 lesion * Is pregnant, is breast feeding women, or women of childbearing age who cannot practice effective contraceptives; * Patients participating in other clinical trials at the same time; * Has severe organ dysfunction (cardiopulmonary liver and kidney) insufficiency, left ventricular ejection fraction (LVEF) \< 50% (cardiac ultrasound); severe cardio cerebral vascular disease within the 6 months previous of randomization (such as unstable angina, chronic heart failure, uncontrolled hypertension with blood pressure\>150/90mmgh, myocardial infarction, or cerebral blood vessel); diabetic patients with poor blood glucose control; patients with severe hypertension; * Has severe or uncontrolled infection; * the researchers judged patients to be unsuitable for the study.
Conditions Prostate Cancer, Breast Cancer, Colon Ca...
Phase Not Applicable
Enrollment 1750
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate. This study does not involve treatment. Participants will have about 50 ml (3 tablespoonfuls) of blood drawn. Depending on their condition, patients may be invited to enroll in a clinical research study involving chemotherapy, radiotherapy, or surgery. Additional 40-ml blood samples may be drawn during the course of treatment. ...

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Undertake genetic analysis of both prokaryotic and eukaryotic samples for advanced mutational analysis. (ongoing)
  • Correlate analysis results with clinical parameters such as demographics, toxicities, and treatment outcomes. (ongoing)
  • Collection of tissue, urine, saliva, stool and blood components, which include serum, leukocytes, peripheral blood mononuclear cells (PBMC), and circulating tumor cells (cTC), of human subjects. (ongoing)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2002-07-16
Completion: Ongoing
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 1750 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Cancer Institute (NCI)
Principal Investigators:
  • Jennifer L Marte (PRINCIPAL_INVESTIGATOR) - National Cancer Institute (NCI)
Contact Information
Study Contact:
Michell J Manu, R.N.
(240) 529-3415
michell.manu@nih.gov
Jennifer L Marte
(301) 496-7214
martej@mail.nih.gov
National Cancer Institute Referral Office
888-624-1937
ncimo_referrals@mail.nih.gov
National Institutes of Health Clinical Center
Interventions
N/A
Study Locations (1 sites)
National Institutes of Health Clinical Center, Bethesda, Maryland 20892 United States
Eligibility Criteria
* INCLUSION CRITERIA: Patients with a known or suspected malignancy and healthy volunteers 18 years of age and older are eligible. Performance status of ECOG 0, 1, 2, or 3 for admission to this protocol. Ability to understand and the willingness to sign a written informed consent document. INCLUSION FOR APHERESIS: Note: Effective with Amendment CC, participants will no longer be asked to undergo apheresis. This content is being retained for historical reference. Hemoglobin greater than or equal to 10 mg/dL and platelet count \> 75,000/mm(3) Weight greater than 25 kg HIV negative Prothrombin Time - within normal limits Partial Thromboplastin Time - within normal limits Medically indicated central line in place or adequate peripheral venous access EXCLUSION CRITERIA: None.
Conditions Triple Negative Breast Cancer
Phase PHASE2
Enrollment 124
Locations 47 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

To study the efficacy, safety, pharmacokinetics and immunogenicity of BCD-236 in combination with chemotherapeutic agents (CHT) in 2nd and subsequent lines of therapy of subjects with relapsed and/or metastatic triple negative breast cancer (TNBC).

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: BCD-236 — as an intravenous infusion
  • Drug: Chemotherapy — CHT (at the investigator's discretion):

Primary Outcomes

  • Overall response rate (ORR) (24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-07-15
Completion: 2027-05
Eligibility
Age: 18 Years – 74 Years
Sex: FEMALE
Volunteers: false
Enrollment: 124 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Biocad
Principal Investigators:
  • Arina V Zinkina-Orikhan, PhD (STUDY_DIRECTOR) - Director of Clinical Development Department, BIOCAD
Contact Information
Study Contact:
Evgenia А Mikhailova
+7 911 081 23 68
mikhailova@biocad.ru
Vitaly S Volkov
+375 162 53 13 87
brcoc@brest.by
Health Institution "Brest Regional Oncology Center"
Vasily N Belyakovsky
+375 232 20 76 00
mail@gokod.by
"Gomel Regional Clinical Oncology Dispensary"
Interventions
  • Biological: BCD-236 — as an intravenous infusion
  • Drug: Chemotherapy — CHT (at the investigator's discretion):
Study Locations (47 sites)
Health Institution "Brest Regional Oncology Center", Brest, Belarus
"Gomel Regional Clinical Oncology Dispensary", Homyel, Belarus
Minsk City Oncology Center, Minsk, Belarus
State Budgetary Institution of Healthcare of the Arkhangelsk Region "Arkhangelsk Clinical Oncology Dispensary", Arkhangelsk, Russia
Regional State Budgetary Healthcare Institution "Altai Regional Oncology Dispensary", Barnaul, Russia
SBHI "Chelyabinsk regional clinical center Oncology and nuclear medicines", Chelyabinsk, Russia
Budgetary healthcare institution of the Udmurt Republic "Republican clinical oncology dispensary named after Sergei Grigorievich Primushko of the Ministry of Health of the Udmurt Republic, Izhevsk, Russia
SBHI of the Kaluga Region "Kaluga Regional Clinical Oncology Center", Kaluga, Russia
State Autonomous Institution of Health "Republican Clinical Oncological Dispensary of the Ministry of Health of the Republic of Tatarstan named after prof. M.Z.Sigal", Kazan', Russia
SBHI "Clinical oncological Dispensary № 1" of the Ministry of Health of the Krasnodar Territory, Krasnodar, Russia
Eligibility Criteria
Main Inclusion Criteria: * Signed informed consent and the subject's ability to comply with the requirements of the Clinical Study Protocol. * Age ≥18 years and \<75 years at the time of signing the informed consent form. * Histologically verified diagnosis (there are documented results of relevant studies) of TNBC: ER 0-2 points, PR 0-2 points or ER \<1%, PR \<1% (ASCO/CAP); HER2 (≤1+) or HER2 (2+) in the absence of amplification of the Her-2-neu gene by ISH. * TNBC is progressive or relapsing on or after systemic therapy. * The subject received at least 1 line of systemic therapy for locally advanced unresectable or metastatic TNBC, or she experienced a relapse / progressive disease during or within 6 months after completion of post-operative (adjuvant) chemotherapy. * Confirmed AXL expression in tumor cells according to immunohistochemistry. * Availability of fresh (obtained as part of screening or before its start, but after disease progression or relapse on the last line of therapy) and archival (obtained before disease progression or relapse on the last line of therapy, if available) tumor material samples suitable for immunohistochemical examination to determine AXL expression. * Presence of at least 1 measurable tumor lesion according to RECIST 1.1. criteria for CIR. * ECOG score 0-1. * Life expectancy ≥ 4 months from the date of signing of the informed consent form in the opinion of the Investigator. Main Exclusion Criteria: * Indications for radical therapy or radiotherapy (excluding minor surgery or radiation therapy for palliative purposes). * Active CNS metastases and/or carcinomatous meningitis. Subjects with brain metastases may participate in the study provided that the metastases have been adequately treated with surgery or radiotherapy, and if they have been clinically stable for at least 4 weeks prior to randomization (i.e. no neurological symptoms, no need for corticosteroids, and no lesions \>1.5 cm) and no evidence of new or increasing CNS metastases. Patients with newly diagnosed CNS metastases during screening may not be included in the study.
Conditions Breast Cancer, Breast Reconstruction
Phase PHASE2
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this clinical trial is to evaluate the cosmetic effect of breast reconstruction based on 3D-printed biodegradable material breast implants in personalized breast reconstruction and the quality of life of patients, with traditional breast-conserving surgery and traditional breast reconstruction as controls. It will also explore the safety of breast reconstruction based on 3D-printed biodegradable material breast implants in personalized breast reconstruction. The main question it aims to answer is: Can breast cancer patients who are not suitable for breast-conserving surgery use 3D-printed biodegradable material breast implants for breast reconstruction? Do patients who undergo breast reconstruction based on 3D-printed biodegradable material breast implants have advantages over those who receive breast-conserving surgery or traditional silicone prosthesis breast reconstruction surgery in terms of cosmetic effects, quality of life and safety? What medical problems may occur when participants use 3D-printed biodegradable material-based breast implants for breast reconstruction? Participants will: Non-random enrollment. In the experimental group, breast reduction surgery based on 3D-printed degradable biological implants was received; In control group 1, traditional breast-conserving surgery was received; Traditional silicone prosthesis breast reconstruction was received in control Group 2.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Breast restoration surgery based on 3D printed degradable biological implants — In the experimental group, the surgeon makes an incision on the skin and creates an electrosurgical free flap with a thickness of approximately 3mm. Based on the tumor size simulated by the computer and combined with real-time exploration during the operation, the tumor is resected. The incision margin is more than 1cm away from the tumor boundary. Eight to ten points are selected at equal intervals around the resected specimen. Samples are taken and sent for frozen tissue pathological section examination to ensure a negative incision margin (those with a positive incision margin are excluded from the clinical trial). Corresponding surgical treatment is provided. Axillary lymph node dissection or sentinel lymph node biopsy is routinely performed. The wound is soaked and rinsed, hemostasis is thoroughly achieved, the designed 3D printed filler is implanted, and sutured and fixed. After placing the drainage, the skin is sutured layer by layer. The corresponding operation time is recorde.
  • Procedure: Traditional breast-conserving surgery — In the control group undergoing traditional breast - saving surgery, tumor segment resection is performed according to the clinical routine. The resection margin is more than 1cm away from the tumor boundary. Eight to ten points are selected at equal intervals around the circumferential specimens after resection. Samples are taken and sent for frozen tissue pathological section examination to ensure a negative resection margin. The volume of the resected part during the intraoperative section is replaced by autologous tissue. Axillary lymph node dissection or sentinel lymph node biopsy is routinely performed. The corresponding operation time is recorded.
  • Procedure: Traditional silicone prosthesis breast reconstruction — In the control group of traditional prosthesis reconstruction, subcutaneous gland resection with nipple and areola preservation combined with prosthesis for concurrent breast reconstruction is carried out according to the clinical routine. The incision method is selected by the surgeon. During the operation, the tissue behind the nipple is sent for frozen tissue pathological section examination to ensure a negative incision margin (those with a positive incision margin are considered out of the clinical trial and given corresponding surgical treatment), and the surgeon decides whether to use the patch in combination. The corresponding operation time is recorded.

Primary Outcomes

  • Postoperative cosmetic effects and quality of life (One year after the operation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-05-01
Completion: 2028-12-31
Eligibility
Age: 18 Years – 70 Years
Sex: FEMALE
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Xijing Hospital
Contact Information
Study Contact:
Ju liang J L Zhang
029-84775271
vascularzhang@163.com
Ju liang J L Zhang
029-84775271
vascularzhang@163.com
Xijing hospital
Interventions
  • Procedure: Breast restoration surgery based on 3D printed degradable biological implants — In the experimental group, the surgeon makes an incision on the skin and creates an electrosurgical free flap with a thickness of approximately 3mm. Based on the tumor size simulated by the computer and combined with real-time exploration during the operation, the tumor is resected. The incision margin is more than 1cm away from the tumor boundary. Eight to ten points are selected at equal intervals around the resected specimen. Samples are taken and sent for frozen tissue pathological section examination to ensure a negative incision margin (those with a positive incision margin are excluded from the clinical trial). Corresponding surgical treatment is provided. Axillary lymph node dissection or sentinel lymph node biopsy is routinely performed. The wound is soaked and rinsed, hemostasis is thoroughly achieved, the designed 3D printed filler is implanted, and sutured and fixed. After placing the drainage, the skin is sutured layer by layer. The corresponding operation time is recorde.
  • Procedure: Traditional breast-conserving surgery — In the control group undergoing traditional breast - saving surgery, tumor segment resection is performed according to the clinical routine. The resection margin is more than 1cm away from the tumor boundary. Eight to ten points are selected at equal intervals around the circumferential specimens after resection. Samples are taken and sent for frozen tissue pathological section examination to ensure a negative resection margin. The volume of the resected part during the intraoperative section is replaced by autologous tissue. Axillary lymph node dissection or sentinel lymph node biopsy is routinely performed. The corresponding operation time is recorded.
  • Procedure: Traditional silicone prosthesis breast reconstruction — In the control group of traditional prosthesis reconstruction, subcutaneous gland resection with nipple and areola preservation combined with prosthesis for concurrent breast reconstruction is carried out according to the clinical routine. The incision method is selected by the surgeon. During the operation, the tissue behind the nipple is sent for frozen tissue pathological section examination to ensure a negative incision margin (those with a positive incision margin are considered out of the clinical trial and given corresponding surgical treatment), and the surgeon decides whether to use the patch in combination. The corresponding operation time is recorded.
Study Locations (1 sites)
Xijing hospital, Xi'an, Shaanxi 710032 China
Eligibility Criteria
Inclusion Criteria: * Female patients with newly diagnosed primary breast cancer, aged 18 to 70 years, confirmed by histopathology. * Willing to undergo breast-conserving surgery, concurrent silicone prosthesis breast reconstruction, or breast reconstruction with 3D-printed biodegradable material breast implants. * Having indications for subcutaneous glandectomy that preserves the nipples and areolas. * ECOG performance status score: 0-1. * If receiving neoadjuvant chemotherapy, the interval between chemotherapy completion and surgery is less than 8 weeks. * Good compliance with the planned treatment, ability to understand the study procedures, and willingness to sign the written informed consent form. Exclusion Criteria: * Age \> 70 years. * Newly diagnosed stage IV metastatic breast cancer. * Multicentric, extensive, or diffuse lesions; or inflammatory breast cancer. * Tumor invasion of the papillary areola complex. * Inability to accept/tolerate radiotherapy. * Breast cancer during pregnancy. * History of other malignant tumors within the past five years (except cured cervical carcinoma in situ and non-melanoma skin cancer). * Abnormal functions of vital organs (heart, lungs, liver, kidneys), poorly controlled diabetes, or other conditions that preclude surgery tolerance. * Patients deemed unsuitable for participation by the researchers.
Conditions HER2 Mutation-Related Tumors, HER2, HER2...
Phase PHASE1
Enrollment 383
Locations 53 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: IAM1363 — IAM1363 monotherapy OR IAM1363 in combination with capecitabine + trastuzumab OR IAM1363 in combination with capecitabine + zanidatamab OR IAM1363 in combination with T-Dxd OR IAM1363 in combination with pembrolizumab +/- carboplatin and pemetrexed

Primary Outcomes

  • Incidence and severity of dose limiting toxicities (DLTs) (Part 1 only) (21 days)
  • Incidence and severity of adverse events (AEs) (Through 30 days after the last dose of study drug)
  • Pharmacokinetic (PK) parameters (Up to 42 days)
  • Confirmed objective response rate (cORR) (Through study completion, estimated as 46 months)
  • Confirmed central nervous system ORR (CNS-cORR) (Through study completion, estimated as 46 months)
  • Frequency of IAM1363 dose modifications, including treatment discontinuations (Through 30 days after the last dose of study drug)
  • Incidence and severity of clinical laboratory abnormalities (Through 30 days post last dose of study drug)
  • Incidence of ECG abnormalities (Through 30 days after the last dose of study drug)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2024-03-25
Completion: 2028-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 383 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Iambic Therapeutics, Inc
Principal Investigators:
  • Iambic Therapeutics, Inc., Senior Medical Director (STUDY_DIRECTOR) - Iambic Therapeutics, Inc
Contact Information
Study Contact:
Iambic Therapeutics, Inc., Senior Medical Director
619-330-5499
ClinicalTrials@Iambic.ai
hopeteam@startresearch.com
START Mountain Region
Interventions
  • Drug: IAM1363 — IAM1363 monotherapy OR IAM1363 in combination with capecitabine + trastuzumab OR IAM1363 in combination with capecitabine + zanidatamab OR IAM1363 in combination with T-Dxd OR IAM1363 in combination with pembrolizumab +/- carboplatin and pemetrexed
Study Locations (53 sites)
UCSD Moores Cancer Center, La Jolla, California 92093 United States
USC Norris Comprehensive Cancer Center, Los Angeles, California 90089 United States
University of Colorado Cancer Center, Aurora, Colorado 80045 United States
University of Miami, Miami, Florida 33136 United States
Comprehensive Hematology Oncology, St. Petersburg, Florida 33709 United States
University of Chicago, Chicago, Illinois 60637 United States
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
Dana Farber Cancer Institute, Boston, Massachusetts 02215 United States
University of Michigan, Ann Arbor, Michigan 48109 United States
Henry Ford Cancer Institute, Detroit, Michigan 48202 United States
Eligibility Criteria
Key Inclusion Criteria: * Age ≥ 18 years * Have relapsed/refractory HER2-altered malignancy; for selected cohorts, prospective confirmation of HER2 alteration by central testing is required * Have progression of disease after the last systemic therapy, or be intolerant of last systemic therapy * Have radiographically measurable disease by RECIST v1.1 and/or RANO-BM * Eastern Cooperative Oncology Group (ECOG) performance score 0-1 * Have adequate baseline hematologic, liver and renal function * Have left ventricular ejection fraction (LVEF) ≥ 50% * Able to swallow oral medication Key Exclusion Criteria: * Clinically significant cardiac disease * Infection with human immunodeficiency virus (HIV)-1 or HIV-2. Exception: Participants with well-controlled HIV (e.g., CD4 \>350/mm3 and undetectable viral load) are eligible * Current active liver disease including hepatitis A, hepatitis B , or hepatitis C * Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant small bowel resection that would preclude adequate absorption * Uncontrolled diabetes * History of solid organ transplantation * History of Grade ≥2 CNS hemorrhage, or any CNS hemorrhage within 28 days before C1D1 * Prior history of non-infectious interstitial lung disease (ILD). (Exceptions: participants with prior grade 1 ILD that has completely resolved are eligible) * Participants requiring immediate local therapy for brain metastases
Conditions HER2-Expressing Solid Tumors
Phase PHASE1
Enrollment 60
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

This clinical trial is designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of MT-304 in adults with advanced HER2-expressing solid tumors. The main questions it aims to answer are: * What is the safety profile of MT-304 when administered alone or with nivolumab? * What is the recommended Phase 2 dose (RP2D) of MT-304? Participants will: * Receive MT-304 alone (every 14 days) or with nivolumab (every 28 days). * Attend regular clinic visits for assessments and monitoring. * Continue treatment until disease progression, unacceptable toxicity, or study discontinuation.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: MT-304 — Safety, tolerability, and pharmacokinetics will be evaluated.
  • Drug: MT-304 + Nivolumab — Combination therapy begins after monotherapy dose clearance by the Safety Review Committee.

Primary Outcomes

  • Type, incidence and severity of Adverse Events (Up to 90 days from the last dose of Investigational Medicinal Product (IMP))
  • Number of Participants With Change From Baseline in Vital Signs (Composite Safety Outcome) (Up to 30 days from the last dose of IMP)
  • Number of Participants With Abnormal Clinical Laboratory Parameters (Composite Safety Outcome) (Up to 30 days from the last dose of IMP)
  • Number of Participants With Change From Baseline in ECG Parameters (Composite Safety Outcome) (Screening through Day 28, with assessments performed on Screening, Day 1 (pre-dose), and Day 28.)
  • Maximum Tolerated Dose (MTD) (28 days from the last dose of IMP)
  • Optimal Biological Dose (OBD) (28 days from the last dose of IMP)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-11-25
Completion: 2028-03-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Myeloid Therapeutics
Collaborators: CREATE Medicines
Principal Investigators:
  • Matthew Maurer, MD (STUDY_DIRECTOR) - Myeloid Therapeutics
Contact Information
Study Contact:
Project Manager
+61731376255
MTX-HER2-304_ClinicalStudy@novotech-cro.com
Clinical Department
+16174651022
mt-304.clinical@createmedicines.com
Dr Rasha Cosman
+61393555655
The Kinghorn Cancer Centre
Interventions
  • Drug: MT-304 — Safety, tolerability, and pharmacokinetics will be evaluated.
  • Drug: MT-304 + Nivolumab — Combination therapy begins after monotherapy dose clearance by the Safety Review Committee.
Study Locations (7 sites)
The Kinghorn Cancer Centre, Darlinghurst, New South Wales 2010 Australia
Scientia Clinical Research Ltd, Randwick, New South Wales 2031 Australia
Calvary Mater Newcastle, Waratah, New South Wales 2298 Australia
Icon Cancer Centre South Brisbane, South Brisbane, Queensland 4101 Australia
Cancer Research SA Pty Ltd, Adelaide, South Australia 5000 Australia
Cabrini Health, Melbourne, Victoria 3144 Australia
Linear Clinical Research, Nedlands, Western Australia 6009 Australia
Eligibility Criteria
Inclusion Criteria: * Aged 18 years or above * Histologically confirmed diagnosis of metastatic or advanced epithelial cancer expressing HER2 (Note: Participants with other tumor types expressing HER2 may be considered pending discussion with the Medical Monitor). * Measurable lesion per RECIST 1.1 criteria. * Eastern Cooperative Oncology Group (ECOG) performance status Grade of 0 or 1. * Adequate Organ function Exclusion Criteria: * Known active CNS metastasis and/or carcinomatous meningitis. * Any acute illness including fever. * History of symptomatic congestive heart failure * History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease. * Uncontrolled pleural effusion, pericardial effusion, or ascites * Active autoimmune disease not related to prior therapy for primary malignancy that has required systemic therapy in the last 1 year.
Conditions Breast Cancer, Ultrasound, Elastography,...
Phase Not Applicable
Enrollment 2000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

Little is known about the correlation between ultrasound characteristics (conventional, elastography and contrast enhanced ultrasound (CEUS) )and pathological prognostic factors in breast cancer. The aim of this study was to explore the correlation between ultrasound characteristics and pathological prognostic factors using radiomics.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Combination Product: Endocrine therapy — Endocrine therapy

Primary Outcomes

  • metastasis (through study completion, an average of 1 year)
  • death (through study completion, an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2018-01-01
Completion: 2028-12
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 2000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
Principal Investigators:
  • pintong Huang (PRINCIPAL_INVESTIGATOR) - Second Affiliated Hospital, Zhejiang University, School of Medicine
Contact Information
Study Contact:
zimei Lin
+8615157171799
zimei.lin@zju.edu.cn
jifan Chen
+8613605771565
jifanchen@zju.edu.cn
zimei Lin
+86151517171799
zimei.lin@zju.edu.cn
the Second Affiliated Hospital Zhejiang University School of Medicine
Interventions
  • Combination Product: Endocrine therapy — Endocrine therapy
Study Locations (1 sites)
the Second Affiliated Hospital Zhejiang University School of Medicine, Hanzhou, Zhejiang 310009 China
Eligibility Criteria
Inclusion Criteria: Clinical diagnosis of breast cancer Exclusion Criteria: Missing pathology Missing follow-up results Missing data
Conditions Breast Neoplasm
Phase NA
Enrollment 25
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to determinate if therapeutic exercise with blood flow restriction (BFR) during neoadjuvant chemotherapy potentialy neurotoxic could prevent the onset of chemotherapy induced peripheral neuropathy (CIPN) comparing to usual care.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Other: PRESIONA — Aerobic and strength exercise combined with restricction blood flow cuffs during chemotherapy treatment

Primary Outcomes

  • Patient-reported CIPN symptoms (Change from Baseline to 12 weeks (after intervention))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-01-01
Completion: 2027-01-01
Eligibility
Age: 18 Years – 70 Years
Sex: FEMALE
Volunteers: false
Enrollment: 25 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universidad de Granada
Principal Investigators:
  • Irene Cantarero-Villanueva, PhD (PRINCIPAL_INVESTIGATOR) - Physical Therapy Deparment, Faculty of Health Sciences, University of Granada
Contact Information
Study Contact:
Irene Cantarero-Villanueva, PhD
958248764
irenecantarero@ugr.es
Irene Cantarero-Villanueva, PhD
958248764
irenecantarero@ugr.es
University of Granada
Noelia Galiano-Castillo, Phd
University of Granada
Interventions
  • Other: PRESIONA — Aerobic and strength exercise combined with restricction blood flow cuffs during chemotherapy treatment
Study Locations (1 sites)
University of Granada, Granada, 18016 Spain
Eligibility Criteria
Inclusion Criteria: * 18 years or older * HER2+ breast cancer diagnosis * On the waiting list to anticancer medical treatment (taxanes-based neoadjuvant chemotherapy) Exclusion Criteria: * Previous diagnosis of cancer * Pregnant * Cardiac pathology * No symptoms or pathology that could be confused with neuropathy or related to diabetes * No recommendation from oncologist for therapeutic exercise practice
Conditions Breast Cancer, Early Breast Cancer
Phase PHASE3
Enrollment 4300
Locations 709 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Camizestrant — Camizestrant. Experimental. Administered orally
  • Drug: Tamoxifen — Tamoxifen. Comparator. Administered per local approved label
  • Drug: Anastrozole — Anastrozole. Comparator. Administered per local approved label
  • Drug: Letrozole — Letrozole. Comparator. Administered per local approved label
  • Drug: Exemestane — Exemestane. Comparator. Administered per local approved label

Primary Outcomes

  • Invasive breast cancer-free survival (IBCFS) (Up to 10 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-03-31
Completion: 2036-05-29
Eligibility
Age: 18 Years – 130 Years
Sex: ALL
Volunteers: false
Enrollment: 4300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AstraZeneca
Contact Information
Study Contact:
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
AstraZeneca Breast Cancer Study Locator Service
1-877-400-4655
az-bcsl@careboxhealth.com
Interventions
  • Drug: Camizestrant — Camizestrant. Experimental. Administered orally
  • Drug: Tamoxifen — Tamoxifen. Comparator. Administered per local approved label
  • Drug: Anastrozole — Anastrozole. Comparator. Administered per local approved label
  • Drug: Letrozole — Letrozole. Comparator. Administered per local approved label
  • Drug: Exemestane — Exemestane. Comparator. Administered per local approved label
Study Locations (709 sites)
Research Site, Birmingham, Alabama 35205 United States
Research Site, Dothan, Alabama 36303 United States
Research Site, Anchorage, Alaska 99508 United States
Research Site, Chandler, Arizona 85224 United States
Research Site, Hot Springs, Arkansas 71913 United States
Research Site, Anaheim, California 92801 United States
Research Site, Beverly Hills, California 90211 United States
Research Site, Concord, California 94520 United States
Research Site, Corona, California 92882 United States
Research Site, Fountain Valley, California 92708 United States
Eligibility Criteria
Inclusion Criteria: * Women and Men, ≥18 years at the time of screening (or per national guidelines) * Histologically confirmed ER+/HER2- early-stage resected invasive breast cancer with high or intermediate risk of recurrence, based on clinical-pathological risk features, as defined in the protocol. * Completed adequate (definitive) locoregional therapy (surgery with or without radiotherapy) for the primary breast tumour(s), with or without (neo)adjuvant chemotherapy * Completed at least 2 years but no more than 5 years (+3 months) of adjuvant ET (+/- CDK4/6 inhibitor) * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 * Adequate organ and marrow function Exclusion criteria: * Inoperable locally advanced or metastatic breast cancer * Pathological complete response following treatment with neoadjuvant therapy * History of any other cancer (except non-melanoma skin cancer or carcinoma in situ of the cervix or considered at very low risk of recurrence per investigator judgement) unless in complete remission with no therapy for a minimum of 5 years from the date of randomisation * Any evidence of severe or uncontrolled systemic diseases which, in the investigator's opinion precludes participation in the study or compliance * Known LVEF \<50% with heart failure NYHA Grade ≥2. * Mean resting QTcF interval \>480 ms at screening * Concurrent exogenous sex hormone therapy * Any concurrent anti-cancer treatment not specified in the protocol with the exception of bisphosphonates (e.g. zoledronic acid) or RANKL inhibitors (eg, denosumab) * Previous treatment with camizestrant, investigational SERDs/investigational ER targeting agents, or fulvestrant * Currently pregnant (confirmed with positive serum pregnancy test) or breastfeeding * Patients with known hypersensitivity to active or inactive excipients of camizestrant or drugs with a similar chemical structure or class to camizestrant. In pre-/peri-menopausal female and male patients, known hypersensitivity or intolerance to LHRH agonists, that would preclude the patient from receiving any LHRH agonist
Conditions Breast Cancer
Phase Not Applicable
Enrollment 4500
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to assess the clinical outcomes in real-life setting of early breast cancer RH+ HER2- patients with systemic therapy guided by Oncotype DX (ODX) Breast Recurrence Score®.

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Primary Outcomes

  • to evaluate the clinical outcomes represented by iDFS in French early breast cancer patients with Oncotype DX (ODX) Breast Recurrence Score® (RS) results-guided therapy (time between surgery and recurrence (local, regional, distant), contralateral breast cancer, second cancer or death (all causes), whichever occurs first, assessed up to 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-10-15
Completion: 2029-03
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 4500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Hospitalier Universitaire de Besancon
Principal Investigators:
  • Elsa CURTIT (PRINCIPAL_INVESTIGATOR) - Centre Hospitalier Universitaire de Besancon
Contact Information
Study Contact:
Elise ROBERT
+33381219086
e1robert@chu-besancon.fr
Diane BERTHOD
+33370632403
dberthod@chu-besancon.fr
Elsa CURTIT, MD
CHU Besançon
Interventions
N/A
Study Locations (5 sites)
CHU Besançon, Besançon, 25030 France
Clinique Tivoli Ducos, Bordeaux, 33000 France
Polyclinique Bordeaux Nord Aquitaine, Bordeaux, 33300 France
AP-HP - Hôpital Tenon, Paris, 75610 France
Centre Catalan d'Oncologie, Perpignan, 66000 France
Eligibility Criteria
Inclusion Criteria: * Patients ≥ 18 years old With invasive breast carcinoma diagnosed on biopsy or surgical sample (histological evidence) Operable breast cancer HR+ (at least ER+) /HER2- tumors With ODX assay performed Exclusion Criteria: * Inoperable tumor(s) or inoperable patient (e.g., patient too frail to undergo surgery) Synchronous breast cancers with different clinico-pathological features (e.g. : HR+/HER2 negative and triple-negative or HER2-positive breast cancer Patient undergoing neoadjuvant chemotherapy or neoadjuvant hormone therapy Nodal involvement in more than 4 lymph nodes (pN2 or higher) Metastatic breast cancer at diagnosis Other malignancy diagnosed in the past 10 years (except for cutaneous malignancies other than melanoma) The patient participated in the RxPONDER study in France The patient communicated a refusal to participate in the study (via a refusal letter to the investigator) Legal incapacity or limited legal capacity
Conditions Cancer (Colon Cancer, Breast Cancer, Lym...
Phase NA
Enrollment 164
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

The treatment of colorectal cancer, in the absence of metastases, is primarily based on surgical removal. Colorectal surgery, which involves resecting part of the intestine and restoring intestinal continuity, carries a risk of complications. This study aims to evaluate whether oral supplementation with a postbiotic at a dose of 900 mg for 7 days prior to surgery reduces the rate of postoperative complications.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Quadruple

Interventions / Regimen

  • Dietary Supplement: Postbiotic — Butyrate directly influences the gastrointestinal microbiota and exhibits potent anti-inflammatory effects by locally inhibiting inflammatory mediators in the intestinal epithelium, thereby enhancing mucosal barrier integrity. It also mitigates excessive inflammation through the modulation of immune cells, promoting the activity of M2 macrophages and regulatory T cells. Furthermore, butyrate is thought to modulate intestinal receptor hypersensitivity, leading to reduced intraluminal pressure and improved peristaltic function. This mechanism may underlie its therapeutic role in clinical conditions associated with diarrhea and in preventing the loss of water, sodium, chloride, and potassium.
  • Other: Placebo — Participants will receive three oral capsules per day, containing no active substance and identical in appearance to the study capsules, for seven consecutive days.

Primary Outcomes

  • Postoperative complications within 30 days (Clavien-Dindo grade II or higher) (30 days after colorectal cancer surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-01
Completion: 2027-06-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 164 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AC Camargo Cancer Center
Principal Investigators:
  • Samuel A Junior, MD, PhD (PRINCIPAL_INVESTIGATOR) - A.C.Camargo Cancer Center
Contact Information
Study Contact:
Samuel A Junior, MD, PhD
+5511 2189-5020
samuel.aguiar@accamargo.org.br
Bruna E Catin Kupper, PhD
+5511 2189-5010
bruna.catin@accamargo.org.br
Bruna E Catin Kupper, PhD
+55 (11) 2189-5010
bruna.catin@accamargo.org.br
A.C.Camargo Cancer Center
Interventions
  • Dietary Supplement: Postbiotic — Butyrate directly influences the gastrointestinal microbiota and exhibits potent anti-inflammatory effects by locally inhibiting inflammatory mediators in the intestinal epithelium, thereby enhancing mucosal barrier integrity. It also mitigates excessive inflammation through the modulation of immune cells, promoting the activity of M2 macrophages and regulatory T cells. Furthermore, butyrate is thought to modulate intestinal receptor hypersensitivity, leading to reduced intraluminal pressure and improved peristaltic function. This mechanism may underlie its therapeutic role in clinical conditions associated with diarrhea and in preventing the loss of water, sodium, chloride, and potassium.
  • Other: Placebo — Participants will receive three oral capsules per day, containing no active substance and identical in appearance to the study capsules, for seven consecutive days.
Study Locations (1 sites)
A.C.Camargo Cancer Center, São Paulo, São Paulo 01509-010 Brazil
Eligibility Criteria
Inclusion Criteria: * Individuals diagnosed with malignant neoplasm of the large intestine, specifically adenocarcinoma. * Patients over 18 years of age, of both sexes. * Patients who agree to participate in the study and sign the informed consent form. Exclusion Criteria: * Emergency or urgent surgeries. * Cytoreductive surgeries involving intraoperative intraperitoneal chemotherapy. * Extended surgeries for the treatment of recurrent tumors.